This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Winners and Losers: Celgene

Health stocks were mixed Monday as traders received a few earnings reports but didn't see a repeat of last week's merger frenzy.

The Nasdaq Biotechnology index was down 0.3%, while its Amex counterpart was adding 0.5%.

As for the big biotech stocks, Celgene (CELG - Get Report) and Cephalon (CEPH) were down 2.4% and 3.4%, respectively.

Gilead (GILD - Get Report), which last week bid for CV Therapeutics (CVTX), was losing 3.9%. Having been outdone by Gilead, Astellas withdrew its offer for CV Therapeutics on Monday.

Of the higher-volume movers on the Amex Biotech index, Amylin Pharmaceuticals (AMLN) was up 50 cents, or 4.5%, to $11.70.

Among the earnings releases, Cypress Bioscience (CYPB) swung to a second-quarter loss of $7.2 million, or 19 cents a share, as revenue fell and costs increased. Shares were down 5.8%, or 47 cents, but volume was light.

Also, StemCells (STEM) lost 7.3% after announcing that its fourth-quarter loss widened to roughly $10 million, or 11 cents a share, primarily due to a writedown and a charge.

Elsewhere, NPS Pharmaceuticals (NPSP) rose 14.2% to $5.06 a share. The company reported on Friday that it had a fourth-quarter loss. However, a Jefferies & Co. analyst raised his rating for the stock to buy from hold after an update on two late-stage drug programs and further partnership developments.

Checking in on traditional drugmakers, the Amex Pharmaceutical index added 1.4%. AstraZeneca (AZN) added 4.5%, and Eli Lilly (LLY) ticked up 3.4%. Sanofi-Aventis (SNY) moved up 2.9%.

On the losing end, Schering-Plough (SGP), which Merck (MRK - Get Report) plans to buy, gave up 2.8%. Merck lost 1.8%.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CELG $99.59 -3.46%
GILD $87.36 -0.50%
MRK $48.85 -1.37%
AAPL $94.18 -0.10%
FB $103.27 2.20%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs